Antiviral Treatment Results and Side Effects During Treatment in Chronic Hepatitis B Patients

Basit Öğe Kaydı
dc.contributor.authorBulut, Rukiyye
dc.contributor.authorKurt, Esma Kepenek
dc.contributor.authorKandemir, Bahar
dc.contributor.authorErayman, Ibrahim
dc.contributor.authorBitirgen, Mehmet
dc.date.accessioned2024-02-23T14:35:23Z
dc.date.available2024-02-23T14:35:23Z
dc.date.issued2021
dc.departmentNEÜen_US
dc.description.abstractObjective: Hepatitis B virus is an important health problem leading to chronic hepatitis, cirrhosis, and hepatocellular carcinoma. This study aimed to compare the efficacy and side effects of antiviral drugs used in chronic hepatitis B (CHB). Methods: Five hundred seventy-two patients who were followed and treated with CHB in our clinic were evaluated retrospectively. Results: Fifty-six point five of 572 patients were male, 43.5% were female, and the mean age of the patients was 43.4 +/- 12.4. Of the patients, 153 (26.8%) used tenofovir disoproxil fumarate (TDF), 134 (23.4%) telbivudine (LdT), 114 (20%) entecavir (ETC), 92 (16%) lamivudine (LAM), 26 (4.5%) adefovir (ADV), 27 (4.7%) pegylated interpheron alpha (PEG-IFN-alpha), and 26 (4.6%) used PEG-IFN-alpha + nucleoside analogue (NA). No significant difference was detected between the treatment groups in terms of age, sex ratio, fibrosis, histological activity index (HAI) score, baseline platelet, international normalized ratio (INR), alpha-fetoprotein (AFP) values (p>0.05). Seventy (12.3%) of 568 patients were HBeAg (+), 498 (87.7%) were HBeAg (-). At the end of the first year, the virological response rates were 92.5% in LdT, 82.6% in LAM, 72.8% in ETV, 60.7% in TDF, 26.9% in ADV, 22.2% in PEG-IFN-alpha, 65.3% in PEG-IFN-alpha+NA groups. Twenty-three point eight of the patients had treatment changes, and 76.3% of these patients preferred TDF as a new treatment. Virological breakthrough was observed at 43.5% in LAM, 13.4% in LdT, 7% in ETV and 0.6% in TDF groups. At the end of 3, 4, and 5 years without treatment change, all patients who continued TDF, ETV, LdT, ADV, and LAM treatment were HBV DNA negative. HBsAg clearance developed in 13 (2.3%) patients. At least one side effect was observed in 169 (29.5%) of all patients, and the group with the most frequent side effects was PEG-IFN-alpha+NA (92.3%) and PEG-IFN-alpha (77.8%). Amylase increase in LAM (%3.2), CPK increase in LdT (%27.6), CPK increase in TDF (%3.2) groups were the most common side effects. Conclusions: The drug with the lowest virological response rate and the most common side effect is PEG-IFN-alpha, so its use should be limited to selected patient groups. Treatments with the lowest incidence of side effects and development of resistance were found to be with TDF and ETV. Considering the high virological response rates, TDF and ETV should be preferred in the treatment of CHB. When all treatments are evaluated, HBsAg loss and cure rates are inadequate.en_US
dc.identifier.doi10.36519/kd.2021.3672
dc.identifier.endpage197en_US
dc.identifier.issn1301-143X
dc.identifier.issn1309-1484
dc.identifier.issue3en_US
dc.identifier.scopus2-s2.0-85124759434en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage192en_US
dc.identifier.urihttps://doi.org/10.36519/kd.2021.3672
dc.identifier.urihttps://hdl.handle.net/20.500.12452/16003
dc.identifier.volume34en_US
dc.identifier.wosWOS:000756838600006en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isotren_US
dc.publisherDoc Design Informatics Co Ltden_US
dc.relation.ispartofKlimik Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectChronic Hepatitis Ben_US
dc.subjectTenofoviren_US
dc.subjectEntecaviren_US
dc.subjectLamivudineen_US
dc.subjectTelbivudineen_US
dc.subjectInterferonen_US
dc.titleAntiviral Treatment Results and Side Effects During Treatment in Chronic Hepatitis B Patientsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu